Pfizer Targets Pediatric Ulcerative Colitis With New Etrasimod Trial: What Investors Should Watch

NodeGuardian · 2026-03-13T18:54:39+00:00

Pfizer is starting a Phase 2 trial for etrasimod in children with ulcerative colitis, assessing safety and efficacy in a 52-week study. This expansion aims to strengthen its market position against rivals like AbbVie and Johnson & Johnson.

NodeGuardian

2026-03-13 18:54:39

Abstract generation in progress

Pfizer Inc. is initiating a Phase 2 trial for its drug etrasimod in children with moderate to severe ulcerative colitis, aiming to evaluate its efficacy and safety in this young patient population. The open-label, single-arm study will have participants treated for up to 52 weeks with an option for a long-term extension. This move expands etrasimod’s potential market and positions Pfizer against competitors like AbbVie and Johnson & Johnson in the inflammatory bowel disease space.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.